BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23135805)

  • 1. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
    Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
    J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
    Yeo KK; HaDuong JH
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):489-90. PubMed ID: 26907647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
    Imtiaz S; Muzaffar N
    J Pak Med Assoc; 2010 Oct; 60(10):867-9. PubMed ID: 21381624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ifosfamide induced encephalopathy: 15 observations].
    Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
    Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
    Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
    Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
    J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
    Bernard PA; McCabe T; Bayliff S; Hayes D
    J Oncol Pharm Pract; 2010 Dec; 16(4):262-5. PubMed ID: 20118215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide encephalopathy and nonconvulsive status epilepticus.
    Primavera A; Audenino D; Cocito L
    Can J Neurol Sci; 2002 May; 29(2):180-3. PubMed ID: 12035842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
    Gharaibeh EZ; Telfah M; Powers BC; Salacz ME
    J Oncol Pharm Pract; 2019 Oct; 25(7):1784-1786. PubMed ID: 30348070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methylene blue in ifosfamide-induced encephalopathy].
    Koschuth A; Späth-Schwalbe PE; Possinger K
    Dtsch Med Wochenschr; 1996 Sep; 121(39):1210. PubMed ID: 8925751
    [No Abstract]   [Full Text] [Related]  

  • 12. Ifosfamide induced encephalopathy in a child with osteosarcoma.
    Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
    J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe ifosfamide-induced neurotoxicity: a case report.
    Ramos Linares S; Breña Atienza J; Cháfer Rudilla M; Ríos Rull P; Cabello Rodríguez A; Merino Alonso J
    Pharm World Sci; 2010 Apr; 32(2):109-11. PubMed ID: 20033290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of thiamine in managing ifosfamide-induced encephalopathy.
    Hamadani M; Awan F
    J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
    Nishimura H; Enokida H; Nagano S; Yokouchi M; Hayami H; Komiya S; Nakagawa M
    J Artif Organs; 2014 Mar; 17(1):110-3. PubMed ID: 24091438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of ifosfamide induced encephalopathy with methylene-blue].
    Ferrero JM; Eftekari P; Largillier R; Dreyfus G; Namer M
    Bull Cancer; 1995 Jul; 82(7):598-9. PubMed ID: 7549123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
    Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
    J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
    Feyissa AM; Tummala S
    J Neurol Sci; 2014 Jan; 336(1-2):109-12. PubMed ID: 24209900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment with methylene blue of ifosfamide-induced central nervous system effects].
    Demandt M; Wandt H
    Dtsch Med Wochenschr; 1996 Apr; 121(17):575. PubMed ID: 8620831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.